騰盛博藥-B(2137.HK)首日上市收漲3.15%
格隆匯7月13日丨騰盛博藥-B(2137.HK)今日首日上市盤中一度漲6.8%至23.75港元,最終收漲3.15%報22.95港元,成交15.08億港元,換手率9.54%,市值162億港元。該股IPO定價22.25港元,香港公開發售獲292倍認購。公司是一家生物技術公司,致力於推進重大傳染病及其他具有重大公共衞生負擔疾病的療法。公司目前已建立了15款在研產品管線,其中有4款候選藥進入二期期或三期臨牀,公司臨牀進展最快的產品是旨在實現乙肝病毒(HBV)感染治癒的創新療法BRI-835(VIR-2218)和BRII-179(VBI-2601),均處於II期臨牀試驗階段。公司股東陣容強大,投資方包括博裕資本、通和毓承、雲鋒基金、紅杉資本、ARCH、Capital Group、Invesco,、GIC、清池資本、高瓴等。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.